Do I need a medical license to prescribe GLP-1 at my medspa?

You must hold an active medical license (MD, DO, NP, or PA with prescriptive authority) to prescribe GLP-1. If you're a nurse injector or aesthetician without independent prescriptive authority, you must partner with a licensed prescriber—either employed, contracted as medical director, or part of a telehealth network. Verify your state's delegation rules with your state medical board, as some states require physician oversight for NPs and PAs.

What does a good-faith GLP-1 exam need to include?

The prescriber must document weight, BMI, comorbidities (diabetes, hypertension, cardiovascular disease), medication history, and contraindications including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Telehealth exams are legally permissible in most states, but some now require an in-person initial visit. Thin documentation creates liability exposure if a patient experiences pancreatitis, gastroparesis, or thyroid issues.

What's the difference between branded and compounded GLP-1 for my medspa?

Branded products (Wegovy, Zepbound) are FDA-approved with regulated quality but offer thin margins (10–20%) and variable insurance coverage; patient out-of-pocket can exceed $1,000/month. Compounded semaglutide ($200–400/month) and tirzepatide ($300–500/month) are cheaper but unregulated by the FDA—you assume liability for quality, sterility, and potency. If using a compounder, verify state pharmacy board license, USP compliance, and third-party potency testing.

Does insurance cover Wegovy and Zepbound?

Coverage varies widely by plan. Some insurers cover Wegovy or Zepbound for BMI ≥30 or ≥27 with comorbidities; others exclude them or require prior authorization. Many patients are uninsured or underinsured for these medications, making cash-pay pricing a significant barrier. Check individual plan requirements before promising coverage to patients.

What compliance risks come with offering GLP-1 at a medspa?

GLP-1 requires different operational and compliance posture than injectables—prescriber licensing, good-faith exams, and proper documentation are non-negotiable. If sourcing from compounders, you accept regulatory and reputational risk for quality and sterility failures. Liability exposure is real if patients experience adverse events (pancreatitis, gastroparesis) and your exam or sourcing records are inadequate.

How much margin can I make on GLP-1 compared to injectables?

Branded GLP-1 margins are thin (10–20% over acquisition cost), significantly lower than typical aesthetic injectables. Compounded GLP-1 offers higher margins due to lower acquisition cost, but you're accepting regulatory and liability risk. The real revenue opportunity lies in patient retention and upsell to aesthetic services, not GLP-1 margins alone.

Saturday, June 27, 2026 Never be the last to know Go Pro · $20/mo →

Live

SAFETYTirzepatide (Mounjaro/Zepbound) — 140,435 adverse-event reports FDA CLEAREDIntense Pulsed Light Therapy Device — Sanhe LEFIS Electronics Co., Ltd.▼Bausch Health (Solta) -8.71%SAFETYSemaglutide (Wegovy/Ozempic) — 82,911 adverse-event reports FDA CLEAREDBarbed PDO Suture — Sutura Medical Technology, Inc.▲STRATA Skin Sciences +8.33%SAFETYBotox — 75,499 adverse-event reports FDA CLEAREDERBECRYO 2 Cryosurgical Unit and Accessories — Erbe Elektromedizin GmbH ▼The Beauty Health Company (HydraFacial) -7.17%FDA CLEAREDLumiGlam Laser System (SHE-LSP601-3) — Beijing Sano Laser S&T Development Co.,Ltd ▲Eli Lilly +7.04%FDA CLEAREDCurrentBody Skin LED Multi Light Therapy Mask (MK-110D) — The Beauty Tech Group, Ltd.▼STAAR Surgical -5.13%RECALLFDA recall: PAYLESS COMPOUNDERS, LLC — Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 RECALLFDA recall: HTO Nevada Inc. dba Kirkman — MAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bott RECALLFDA recall: Pro Numb Tattoo Numbing Spray LLC — Pro Numb Tattoo Numbing Spray, For Sensiti

Market

Offering GLP-1 Weight Loss at a Medspa: Sourcing, Compliance, and Revenue Model

How to evaluate GLP-1 as a revenue line, navigate sourcing and prescriber requirements, and stay compliant with state and federal regulations.

AI Inside MedSpa Intelligence · Jun 26, 2026

GLP-1 receptor agonists—semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro)—have become a significant revenue opportunity for medspas willing to add a medical-weight-loss vertical. Demand is real: patients already trust you for aesthetic outcomes and are actively seeking non-surgical metabolic solutions. But offering GLP-1 requires a different operational and compliance posture than injectables, and the sourcing and reimbursement landscape is fragmented. Here's what you need to know before you launch.

Demand and Market Reality

Free weekly

Not ready for Pro?

Get the free weekly recap of the moves that matter. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

Bausch Health (Solta) -8.71% STRATA Skin Sciences +8.33% The Beauty Health Company (HydraFacial) -7.17% Eli Lilly +7.04% STAAR Surgical -5.13%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearancesRecalls

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never be the last to know. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →